drugset / Trial / NCT02379663

Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty

NCT02379663

Phase 4 Completed 639 enrolled Samsung Medical Center
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This prospective study compares an oral direct factor Xa inhibitor with LMWH for thromboprophylaxis in the patients undergoing THA.

Timeline

Start
2012-01
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Comparator Rivaroxaban Other / unclassified 10 mg Oral